Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trial
Clicks: 142
ID: 274458
2020
Article Quality & Performance Metrics
Overall Quality
Improving Quality
0.0
/100
Combines engagement data with AI-assessed academic quality
Reader Engagement
Emerging Content
30.0
/100
132 views
25 readers
Trending
AI Quality Assessment
Not analyzed
Abstract
n the EMN01 trial, the addition of an alkylator (melphalan or cyclophosphamide) to lenalidomide-steroid induction therapy was prospectively evaluated in transplant-ineligible patients with multiple myeloma. After induction, patients were randomly assigned ...
| Reference Key |
larocca2020haematologicalenalidomide-based
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Sara Bringhen, Mattia D’Agostino, Laura Paris, Stelvio Ballanti, Norbert Pescosta, Stefano Spada, Sara Pezzatti, Mariella Grasso, Delia Rota-Scalabrini, Luca De Rosa, Vincenzo Pavone, Giulia Gazzera, Sara Aquino, Marco Poggiu, Armando Santoro, Massimo Gentile, Luca Baldini, Maria Teresa Petrucci, Patrizia Tosi, Roberto Marasca, Claudia Cellini, Antonio Palumbo, Patrizia Falco, Roman Hájek, Mario Boccadoro, Alessandra Larocca;Sara Bringhen;Mattia D’Agostino;Laura Paris;Stelvio Ballanti;Norbert Pescosta;Stefano Spada;Sara Pezzatti;Mariella Grasso;Delia Rota-Scalabrini;Luca De Rosa;Vincenzo Pavone;Giulia Gazzera;Sara Aquino;Marco Poggiu;Armando Santoro;Massimo Gentile;Luca Baldini;Maria Teresa Petrucci;Patrizia Tosi;Roberto Marasca;Claudia Cellini;Antonio Palumbo;Patrizia Falco;Roman Hájek;Mario Boccadoro;Alessandra Larocca; |
| Journal | Haematologica |
| Year | 2020 |
| DOI |
10.3324/haematol.2019.226407
|
| URL | |
| Keywords |
|
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.